Monocytes Are Associated with Impaired T-Cell Immunity and Residual Interim-PET/CT Avidity After 4 Cycles of CHOP-R In Patients with High-Risk DLBCL

被引：1
|
作者：
Gandhi, Maher K. [1 ]
Hertzberg, Mark S. [2 ]
Han, Erica [1 ]
Seymour, John F. [3 ]
Hicks, Rodney [4 ]
Gill, Devinder S. [5 ]
Keane, Colm [1 ]
Crooks, Pauline [1 ]
Radford, Kristen [6 ]
Vari, Frank [1 ]
机构：
[1] Queensland Inst Med Res, Brisbane, Qld 4006, Australia
[2] Westmead Hosp, Dept Hematol, Westmead, NSW 2145, Australia
[3] Peter MacCallum Canc Inst, Dept Haematol Tumour Stream, Melbourne, Vic, Australia
[4] Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia
[5] Princess Alexandra Hosp, Div Canc Serv, Brisbane, Qld 4102, Australia
[6] Mater Med Res Inst, Brisbane, Qld, Australia
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
10.1182/blood.V118.21.3673.3673
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1570 / 1570
页数：1
相关论文
共 7 条
  • [1] The T-Cell Receptor Repertoire Predicts Interim-PET in Patients with DLBCL Treated with R-CHOP: An Observational Study from a Prospective Clinical Trial
    Shanavas, Mohamed
    Hertzberg, Mark
    Hicks, Rodney J.
    Seymour, John F.
    Tobin, Joshua W. D.
    Mathews, Marina
    Francis, Santiyagu
    Vari, Frank
    Gandhi, Maher K.
    Keane, Colm
    BLOOD, 2017, 130
  • [2] Early Treatment Intensification With R-ICE And 90Y-Ibritumomab Tiuxetan (Zevalin)-BEAM Stem Cell Transplantation In Patients With High Risk Diffuse Large B-Cell Lymphoma Patients And Positive Interim PET After 4 Cycles Of R-CHOP-14
    Hertzberg, Mark
    Gandhi, Maher K.
    Trotman, Judith
    Butcher, Belinda
    Taper, John
    Johnston, Amanda
    Gill, Devinder
    Ho, Shir-Jing
    Cull, Gavin
    Fay, Keith
    Chong, Geoff
    Grigg, Andrew
    Lewis, Ian D.
    Milliken, Sam
    Renwick, William
    Hahn, Uwe
    Filshie, Robin
    Kannourakis, George
    Watson, Anne-Marie
    Warburton, Pauline
    Wirth, Andrew
    Seymour, John F. S.
    Hofman, Michael S.
    Hicks, Rodney J.
    HAEMATOLOGICA, 2017, 102 (02) : 356 - 363
  • [3] Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after Four Cycles of R-CHOP-14: A Multicenter Phase II Study of the Australasian Leukaemia Lymphoma Study Group (ALLG)
    Hertzberg, Mark S.
    Gandhi, Maher K.
    Butcher, Belinda
    Columbus, Ruth
    Taper, John
    Trotman, Judith
    Gill, Devinder
    Ho, Shir-Jing
    Fay, Kelth
    Cull, Gavin
    Grigg, Andrew P.
    Chong, Geoff
    Lewis, Ian D.
    Milliken, Sam
    Renwick, William
    Hahn, Uwe
    Filshie, Robin
    Watson, Anne-Marie
    Kannourakis, George
    Wolf, Max
    Wirth, Andrew
    Warburton, Pauline Therese
    Larsen, Stephen Robert
    Seymour, John F.
    Hicks, Rodney
    BLOOD, 2015, 126 (23)
  • [4] High Response Rate with Favorable Survival Projections in High-Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving R-CHOP-14 or Early Intensified Chemotherapy with Rituximab and Autograft (R-HDS): Results of the Interim Analysis of A GITIL Prospective Multicenter Phase III Study
    Cortelazzo, Sergio
    Tarella, Corrado
    Gianni, Alessandro M.
    Ladetto, Marco
    Zanni, Manuela
    Corradini, Paolo
    Di Nicola, Massimo
    Patti, Caterina
    Mule, Antonino
    Majolino, Ignazio
    Billio, Atto
    Gueli, Angela
    Di Raimondo, Francesco
    Chiarenza, Annalisa
    Gallamini, Andrea
    Ferreri, Andres
    Pizzolo, Giovanni
    Benedetti, Fabio
    La Nasa, Giorgio
    Leoni, Pietro
    Gini, Guido
    Trentin, Livio
    Rodeghiero, Francesco
    Marchioli, Roberto
    Barbui, Tiziano
    Barbui, Anna
    Rambaldi, Alessandro
    BLOOD, 2009, 114 (22) : 502 - 503
  • [5] Analysis of CMV-specific T-cell immunity by intracellular cytokine staining in patients undergoing allogeneic haematopoietic stem-cell transplantation early after transplant identifies a high-risk group for viremic CMV reactivation
    Benet, I.
    Clari, M.
    Solano, C.
    Nieto, J.
    de la Camara, R.
    Hernandez-Boluda, J. C.
    Remigia, M. J.
    Lopez, J.
    Garcia-Noblejas, A.
    Alberola, J.
    Tamarit, A.
    Gimeno, C.
    Navarro, D.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S278 - S278
  • [6] A GITIL prospective randomized multicenter phase III study of high dose sequential chemotherapy with rituximab (R-HDS) and autologous transplantation (ASCT) of peripheral blood stem cells versus CHOP and rituximab delivered every 14 days (R-CHOP-14) in high-risk patients with diffuse large B-Cell lymphomas (DLBCL): Interim analysis on feasibility and toxicity (protocol R-HDS 0305).
    Cortelazzo, Sergio
    Billio, Atto
    Rambaldi, Alessandro
    Tarella, Corrado
    Majolino, Ingnazio
    Gianni, Alessandro M.
    Corradini, Paolo
    Patti, Catterina
    Mirto, Salvo
    Borrelli, Giovanna
    Marchioli, Roberto
    BLOOD, 2007, 110 (11) : 563A - 563A
  • [7] Cytomegalovirus (CMV)-Specific T-Cell and Humoral Immune Responses in a Randomized Trial of Preemptive Antiviral Therapy (PET) vs Antiviral Prophylaxis (PRO) After High-Risk CMV D plus R-Liver Transplant (LTx)
    Zamora, D.
    Dasgupta, S.
    Wagener, M.
    Akoto, M.
    Edmison, B.
    Stevens-Ayers, T.
    Winston, D.
    Razonable, R.
    Lyon, G. M.
    Mehta, A.
    Silveira, F. P.
    Koelle, D.
    Boeckh, M.
    Singh, N.
    Limaye, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (06) : S603 - S603
1